Women experience physiological and emotional issues during different
phases of their life cycle due to hormonal changes. Women’s health is
especially referred to where reproductive health is involved. According to the
Society for Women’s Health Research in the US, issues specific to the human
female anatomy are defined as women’s health. The biological mechanisms
influence the clinical course of diseases and disorders differently in women
when compared to men. Some of the main women’s health disorders include
infertility, menopause, endometriosis and polycystic ovarian syndrome as well
as urological disorders and cancers such as breast cancer, cervical cancer,
endometrial cancer, and ovarian cancer. In addition, contraception plays an
important role in women’s health for many reasons, so this too is also
categorized under women’s health.
Analysts forecast the Global Women’s Health
market will grow at a CAGR of 3.52 percent over the period
2013-2018.
The Report recognizes the following companies as the key players in the
Global Women's Health Market : Actavis plc, Bayer AG , Eli Lilly and Co., Merck
& Co., Pfizer Inc. , AbbVie Inc., Adamis Pharmaceuticals Corp., Agile
Therapeutics Inc., Amgen Inc., ANI Pharmaceuticals Inc.,
ApothecusPharmaceutical Corp., AstraZeneca plc, Blairex Laboratories Inc.,
Catalysis SL, Crinetics Pharmaceuticals Inc., Dexa Medica Group, EffRx Inc.,
Ferring International Center SA,GlaxoSmithKline plc, HLL Lifecare Ltd., Janssen
Pharmaceutical Inc., Ligand Pharmaceuticals Inc., Lipocine Inc., Lupin
Pharmaceuticals Inc., Mayer Laboratories , Medicines 360,Mylan Laboratories
Inc., Neurocrine Biosciences Inc., Pantarhei Bioscience BV, Teva
Pharmaceuticals Inc.
In the recent past, vendors have entered into several agreements or
partnerships to develop or introduce new products or drugs in the Global
Women's Health market. Some of the major acquisitions include Conceptus by
Bayer, Warner Chilcott by Actavis, Uteron Pharma by Watson Pharmaceuticals, and
Barr Pharmaceuticals by Teva Pharmaceutical. Some of the other prominent
collaborations include Bayer with EndoCeutics to develop Vaginorm for treatment
of vaginal atrophy, AbbVie with Neurocrine Biosciences to develop and
commercialize Elagolix and all next-generation GnRH antagonists for women's and
men's health.
Covered in this
Report
This report covers the present scenario and the growth prospects of the
Global Women’s Health market for the period 2014-2018. To calculate the market
size, the report considers revenue generated from the sales of various products
used for the wellbeing of women, which are listed below based on their
application segment:
- Postmenopausal Osteoporosis (Drugs)
- Hormonal Contraceptives (Drugs and Devices)
- Menopause (Drugs)
- Infertility (Drugs)
- Endometriosis (Drugs)
- Polycystic Ovary Syndrome (Drugs)
Global Women’s Health Market 2014-2018, has been prepared based on an
in-depth market analysis with inputs from industry experts. The report covers
the Americas, the EMEA, and the APAC regions; it also covers the Global Women’s
Health market landscape and its growth prospects in the coming years. The
report also includes a discussion of the key vendors operating in this market.
According to the report, the growth of the Global Women's Health market
is curtailed by some serious challenges. One of the main challenges is the
patent expiry of major blockbuster drugs during the forecast period. Some of
the patent expiries of top leading products include Bayer’s Mirena and Yaz, Eli
Lilly's Evista, and F. Hoffmann-La Roche's Boniva.
Further, the report states that the growth of the Global Women's Health
market is curtailed by some serious challenges. One of the main challenges is
the patent expiry of major blockbuster drugs during the forecast period. Some
of the patent expiries of top leading products include Bayer’s Mirena and Yaz,
Eli Lilly's Evista, and F. Hoffmann-La Roche's Boniva.
